PD59-11 TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION

作者
Hua Xu
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:203 (Supplement 4)
标识
DOI:10.1097/ju.0000000000000969.011
摘要

You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology III (PD59)1 Apr 2020PD59-11 TARGETING BCL2 TO INCREASE ENZALUTAMIDE SENSITIVITY TO BETTER SUPPRESS PROSTATE CANCER PROGRESSION THROUGH ALTERING ARV7 PROTEIN DEGRADATION Hua Xu* Hua Xu*Hua Xu* More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000969.011AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Androgen deprivation therapy (ADT) with antiandrogens targeting androgens/androgen receptor (AR) signaling is the standard used to treat prostate cancer in different clinical settings besides surgical treatment. However, most prostate cancer patients will eventually develop cancer progression despite castrate levels of testosterone, into castration resistant prostate cancer (CRPC). The recently developed antiandrogen, Enzalutamide, has reformed the standard of care for castration resistant prostate cancer patients. However, Enzalutamide resistance inevitably emerges despite success of Enzalutamide in prolonging castration resistant prostate cancer patients’ survival. Here we found that Enzalutamide resistant prostate cancer cells had higher BCL2 expression. We aimed to test whether targeting BCL2 would influence Enzalutamide sensitivity of prostate cancer and identify the potential mechanism. METHODS: The study was designed to target Enzalutamide induced BCL2 with inhibitor ABT263 and test Enzalutamide sensitivity in Enz-resistant prostate cancer cells by MTT assay. Cellular reactive oxygen species levels were detected with dihydroethidium staining, and in vitro deubiquitinating enzyme activity assay was used to evaluate ubiquitin specific protease 26 (USP26) activity. RESULTS: We retrospectively performed an RNA sequencing among 625 CRPC patients and 625 matched hormone-sensitive prostate cancer (HSPC) patients and revealed that BCL2 was significant increased in CRPC, which indicated that targeting BCL2 might be a potential option. BCL2 inhibitor, ABT263 could increase Enzalutamide sensitivity and increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation in both Enzalutamide sensitive and Enzalutamide resistant prostate cancer cells. As BCL2 is a classical anti-apoptosis protein, we then tested the potential linkage of its anti-apoptotic activity to its ability to alter the AR and ARv7 expression. The results revealed that inhibition of BCL2 activity by ABT263 (with and without Enz treatment) resulted in cleaved-PARP expression in both EnzS1-C4-2 and EnzR1-C4-2 and EnzR3-CWR22Rv1 PCa cells, suggesting that ABT263 could promote PCa apoptosis. However, blocking apoptosis through inhibition of caspase activity with Z-VAD-FMK (pan-caspase inhibitor) failed to reverse the decrease of AR and ARv7 protein expression, suggesting that the apoptotic pathway was unlikely responsible for the decrease of AR and ARv7 expression. As BCL2 is a mitochondria protein that may alter the mitochondria function via modulating the ROS, we then tested weather ABT263 could function via altering the cellular ROS to decrease the AR and ARv7 expression to further influence Enzalutamide sensitivity. ABT263 treatment could significantly induce cellular ROS level in both EnzS1-C4-2 and EnzR1-C4-2 and EnzR3-CWR22Rv1 PCa cells. Elevated cellular reactive oxygen species levels might then inhibit USP26 activity to increase the ubiquitination of androgen receptor (AR) and AR splice variant 7 (ARv7) and their ubiquitin/proteasome-dependent degradation, which contributed to the increase of Enz sensitivity. In vivo mouse model also demonstrates that ABT263 will suppress the prostate cancer progression. CONCLUSIONS: This study demonstrated that targeting Enzalutamide induced BCL2 with inhibitor ABT263 could increase Enzalutamide sensitivity in both Enzalutamide sensitive and Enzalutamide resistant prostate cancer cells through induction of cellular reactive oxygen species levels and suppression of USP26 activity with a consequent increase of ubiquitin/proteasome-dependent degradation of AR and ARv7 protein expression. This preclinical study established the foundation to use ABT263 in combination with Enzalutamide to treat prostate cancer patients, especially those resistant to Enzalutamide. Source of Funding: National Natural Science Foundation of China (No. 81472377 and 81802570) © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e1209-e1209 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hua Xu* More articles by this author Expand All Advertisement PDF downloadLoading ...

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
宋艳芳完成签到,获得积分10
2秒前
快乐的幼丝完成签到 ,获得积分0
2秒前
香蕉觅云的应助被大明采纳,获得10
3秒前
CHEN完成签到 ,获得积分10
6秒前
驰骋完成签到 ,获得积分10
7秒前
maple完成签到 ,获得积分10
7秒前
阿冰完成签到 ,获得积分10
8秒前
酷炫映阳完成签到 ,获得积分10
9秒前
怡然的千儿完成签到,获得积分10
10秒前
大明完成签到,获得积分10
11秒前
harden9159完成签到,获得积分10
12秒前
16秒前
仁仁仁完成签到,获得积分10
17秒前
灯座完成签到,获得积分10
19秒前
u雨发布了新的文献求助10
20秒前
Voiceless的应助被Bin_Liu采纳,获得10
23秒前
不吃压力就是干完成签到 ,获得积分10
23秒前
Lingeek完成签到,获得积分10
28秒前
霸气芫完成签到 ,获得积分10
32秒前
32秒前
betty2009完成签到,获得积分10
33秒前
饱满千兰完成签到,获得积分10
34秒前
科研通AI6.3的应助被u雨采纳,获得10
38秒前
王kk完成签到 ,获得积分10
39秒前
哈哈哈完成签到 ,获得积分10
41秒前
邓代容完成签到 ,获得积分0
46秒前
奋斗诗云完成签到 ,获得积分10
48秒前
irisyan完成签到 ,获得积分10
50秒前
白云完成签到 ,获得积分10
51秒前
难过的研究牲完成签到 ,获得积分10
52秒前
大耳朵图图完成签到 ,获得积分10
53秒前
孤狼完成签到 ,获得积分10
57秒前
子良完成签到 ,获得积分10
57秒前
xinxin完成签到 ,获得积分10
58秒前
黑白完成签到 ,获得积分10
58秒前
一诺相许完成签到,获得积分10
1分钟前
领导范儿的应助被文文采纳,获得10
1分钟前
xh完成签到,获得积分10
1分钟前
QwQ完成签到 ,获得积分10
1分钟前
高兴的灰狼完成签到,获得积分20
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012